S100A10是成人胶质瘤中与恶性分子特征及免疫抑制过程相关的新预后生物标志物
研究基于中国胶质瘤基因组图谱325例和癌症基因组图谱699例胶质瘤数据,分析S100A10在成人胶质瘤中的生物学特征与临床意义。发现S100A10在高级别胶质瘤、IDH野生型、1p19q非共缺失型、MGMT启动子非甲基化型及间质样分子亚型中高表达,且与不良生存独立相关,并与免疫抑制性免疫细胞浸润正相关。
要点
- S100A10在高级别胶质瘤、IDH野生型、1p19q非共缺失型、MGMT启动子非甲基化型及间质样亚型中高表达。
- S100A10上调与不良生存独立相关,并特异性指示间质样分子亚型。
- S100A10与肿瘤相关巨噬细胞、调节性T细胞及髓源性抑制细胞浸润正相关。
核心结论
- S100A10与成人胶质瘤恶性病理亚型、较差预后及免疫抑制性免疫细胞浸润密切相关,有望成为胶质瘤诊断、治疗和预后评估的生物标志物及潜在靶点。
研究设计与样本
- 研究纳入中国胶质瘤基因组图谱的325例胶质瘤病例作为训练队列,癌症基因组图谱的699例胶质瘤病例作为验证队列,使用RNA测序数据进行分析。
- 采用单因素方差分析和Student t检验评估组间差异,以P<0.05为差异有统计学意义。
主要发现
- S100A10在高级别胶质瘤、异柠檬酸脱氢酶野生型、1p19q非共缺失型、O6-甲基鸟嘌呤-DNA甲基转移酶启动子非甲基化型及间质样分子亚型中显著高表达。
- S100A10上调水平与不良生存独立相关。
- S100A10相关生物学过程主要集中于免疫反应和炎症反应。
- S100A10与大多数炎症宏基因正相关(IgG除外),包括HCK、LCK、MHC II、STAT1和干扰素。
- 胶质瘤浸润免疫细胞水平与S100A10表达正相关,尤其在肿瘤相关巨噬细胞、调节性T细胞和髓源性抑制细胞中。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Previous studies have demonstrated the role of S100A10 in the progression of several tumors; however, few studies have investigated its immunological characteristics in adult gliomas. In this study, we systematically explored its biological features and clinical significance in adult gliomas. METHODS: Altogether, 325 glioma cases from the Chinese Glioma Genome Atlas and 699 glioma cases from The Cancer Genome Atlas were included as the training and validation cohorts. R software was used for data analysis and mapping using the RNA sequencing data from these cases. One-way analysis of variance and Student's t-test were used to assess the differences between the groups. Differences were considered statistically significant at P < 0.05. RESULTS: We found that S100A10 was remarkably highly expressed in high-grade glioma, isocitrate dehydrogenase wild type, 1p19q noncodeletion type, O6-methylguanine-DNA methyltransferase promoter unmethylation type, and mesenchymal-like molecular subtype. S100A10 specifically and sensitively indicates the mesenchymal-like molecular subtype. Upregulated S100A10 levels were independently correlated with poor survival. S100A10-related biological processes in gliomas mainly concentrate on immunoreaction and inflammatory response. We then proved that S100A10 was positively related to most inflammatory metagenes, except IgG, including HCK, LCK, MHC II, STAT1, and interferon. More importantly, the levels of glioma-infiltrating immune cells were positively associated with the expression of S100A10, especially in tumor-related macrophages, regulatory T cells, and myeloid-derived suppressor cells. CONCLUSIONS: S100A10 is closely related to malignant pathological subtypes, worse prognosis, and immunosuppressive immune cell infiltration in adult gliomas, making it a promising biomarker and potential target in the diagnosis, treatment, and prognostic assessment of gliomas.
引用
- Ma K, Chen S, Chen X, et al. S100A10 Is a New Prognostic Biomarker Related to the Malignant Molecular Features and Immunosuppression Process of Adult Gliomas. World Neurosurg. 2022. PMID: 35779750. doi:10.1016/j.wneu.2022.06.124
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。